Similar articles

• [Clinovir treatment of adenocarcinoma of the uterus with lung metastases].

  Stertmann WA, Hocke M, Röttger P. Stertmann WA, et al. MMW Munch Med Wochenschr. 1983 Jul 22;125(29-30):685-6. MMW Munch Med Wochenschr. 1983. PMID: 6225946 German. No abstract available.
• Endocrinological effects of treatment with high doses of medroxyprogesterone acetate in patients with renal or prostatic adenocarcinoma.

  Tomic R, Ljungberg B, Damber JE. Tomic R, et al. Scand J Urol Nephrol Suppl. 1988;110:185-7. Scand J Urol Nephrol Suppl. 1988. PMID: 2973122 No abstract available.
• [The treatment of metastasizing hypernephroid (renal cell) carcinoma with medroxyprogesterone acetate (Clinovir) (author's transl].

  von Lieven H, Hahn D. von Lieven H, et al. MMW Munch Med Wochenschr. 1977 Aug 26;119(34):1089-92. MMW Munch Med Wochenschr. 1977. PMID: 408657 German.
• The role of medroxyprogesterone acetate (MPA) in the treatment of renal adenocarcinoma.

  Kjaer M. Kjaer M. Cancer Treat Rev. 1988 Sep;15(3):195-209. doi: 10.1016/0305-7372(88)90003-5. Cancer Treat Rev. 1988. PMID: 2974757 Review. No abstract available.
• Clinical significance of differences in bioavailability of medroxyprogesterone acetate preparations.

  Stockdale AD, Rostom AY. Stockdale AD, et al. Clin Pharmacokinet. 1989 Mar;16(3):129-33. doi: 10.2165/00003088-198916030-00001. Clin Pharmacokinet. 1989. PMID: 2524303 Review. No abstract available.